Revolution Medicines Presenting at AACR Virtual Meeting II

Revolution Medicines, Inc. (Nasdaq: RVMD), an Illinois Ventures portfolio company developing targeted therapies to inhibit frontier cancer targets, will present four presentations at the upcoming 2020 American Association for Cancer Research (AACR) Virtual Annual Meeting II being held June 22-24, 2020. 

The presentations topics include SHP2 inhibition as the backbone of targeted therapy combinations for the treatment of cancers driven by oncogenic mutations in the RAS pathway; Positioning a selective, bi-steric inhibitor of mTORC1 as a combination partner in RAS-driven cancers; Dual inhibition of SHP2 and CDK4/6 leads to immunological memory and immune-mediated anti-tumor activity in a mouse syngeneic model of breast cancer; and the Discovery and development of allosteric inhibitors of SHP2.

For further details and for more information on Revolution Medicines, click here.

For more information on the AACR Virtual Annual Meeting, click here.